Status:
ACTIVE_NOT_RECRUITING
Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes
Lead Sponsor:
Biocells Medical
Conditions:
Autoimmune Encephalitis
Early-stage Panencephalitis
Eligibility:
All Genders
6-70 years
Brief Summary
This is a prospective, non-randomized, observational registry study evaluating the clinical outcomes of patients with autoimmune or post-infectious neuroinflammatory syndromes receiving stem cell-deri...
Eligibility Criteria
Inclusion
- • Age 6-70
- Diagnosis of one of the eligible syndromes by neurologist or immunologist
- Unresponsive or partially responsive to conventional therapy
- Informed consent provided
Exclusion
- • Active malignancy
- Severe systemic infection
- Contraindications to IV biologics
Key Trial Info
Start Date :
September 19 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 19 2027
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT07145502
Start Date
September 19 2022
End Date
September 19 2027
Last Update
September 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Biocells Medical
Warsaw, Poland, 01-234